Commercialization Committee
Charter
To position ISCT as a critical global communication hub between therapeutic societies, regulatory policy makers, and institutional stem cell centers and industry for the advancement of clinical investigations in regenerative medicine.
Objectives and Priorities
- To construct a Commercialization Committee with balanced representation of translational medicine stakeholders with a clear charter in support of ISCT strategic objectives
- To establish a new Industry Community within ISCT to communicate and prioritize value relationships between industry and ISCT
- To construct working subcommittees chartered to meet priority commercialization goals identified by industry and ISCT membership
- To identify and create new relationships between industry, therapeutic societies and basic stem cell scientists using global multi-disciplinary workshops and forums
Key Benchmarks 2011
|
Produce Annual Report of CC Activities reflective of ISCT strategic plan and Industry engagement for 2011 Annual Meeting ✓ |
May |
|
Ensure action oriented responsiveness to Industry Community agenda -poll for a fresh list of priorities |
June |
|
Increase Global CC participation and benchmark industry participation at ISCT regional meetings by hosting an industry session or track N America Q3 Asia Q4 |
Septemer, November |
|
Refine CC organization and substructure to reflect growth of Industry Community and to maintain balance with academic translational community |
September |
|
Evaluate and launch on line forum which offers increased access to KOLs |
September |
|
Strengthen CC relationship with ISCT leadership measured by CC participation in global and regional executive committees and in the scientific cell and therapeutic committees. |
December |
|
Represent to the ISCT Executive the CC’s priority list of working alliances with Cell Processing and Regenerative Medicine societies (Q2 )with a commitment to support leadership in alliance development. Measure progress against list Q4 |
June, December |
|
Foster new industry community membership with a focus on the following segments; CROs, financial community & analysts, bioprocessors and bioreactor companies. |
December |
ISCT Commercialization Committee Composition
|
Pharma & |
Cell Therapy |
Industry |
Academics & |
Contract |
|
Genzyme |
Aldagen |
Finance & |
AUZ |
CellGenix |
ISCT Executive Committee Oversight on Committee Membership
If you would like more information about how to get involved, please email isct@celltherapysociety.org.
